Get started
Author

Bridget T. Kreger

Observed names: B. T Kreger, Bridget Kreger, Bridget T. Kreger, Kreger, Bridget
ORCID: 0009-0007-9372-5826
Observed ORCID: 0009-0007-9372-5826
OpenAlex ID: A5047050180
Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation
2011 · Karin Schlegelmilch, Morvarid Mohseni, et al. · Cell · 1,074
PDF
α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1
2011 · Mark R. Silvis, Bridget T. Kreger, et al. · Science Signaling · 359
The Enrichment of Survivin in Exosomes from Breast Cancer Cells Treated with Paclitaxel Promotes Cell Survival and Chemoresistance
2016 · Bridget Kreger, Eric Johansen, et al. · Cancers · 159
PDF
Micro RNA responses to chronic or acute exposures to low dose ionizing radiation
2012 · M. Ahmad Chaudhry, Romaica A. Omaruddin, et al. · Molecular Biology Reports · 87
Microvesicle Cargo and Function Changes upon Induction of Cellular Transformation
2016 · Bridget T. Kreger, Andrew L. Dougherty, et al. · Journal of Biological Chemistry · 58
Transcriptional modulation of micro-RNA in human cells differing in radiation sensitivity
2010 · M. Ahmad Chaudhry, Bridget Kreger, et al. · International Journal of Radiation Biology · 54
Abstract 2158: Preclinical evaluation of CFT1946 as a selective degrader of mutant BRAF for the treatment of BRAF driven cancers
2022 · Mathew E. Sowa, Bridget Kreger, et al. · Cancer Research · 12
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance
2025 · Bridget T. Kreger, Yanke Liang, et al. · Cancer Research · 11
Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
2023 · Yanke Liang, Mathew E. Sowa, et al. · Cancer Research · 10
Cft7455: a Novel, Ikzf1/3 Degrader That Demonstrates Potent Tumor Regression in a Spectrum of Nhl Xenograft Models
2021 · S Perino, B Class, et al. · Hematological Oncology · 5
Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
2023 · Yanke Liang, Mathew E. Sowa, et al. · Cancer Research · 2
Abstract 1658: CFT1946, a potent, selective BRAF V600X mutant-specific degrader demonstrates superior activity as a single agent to clinically approved BRAF inhibitors and standard of care combinations in preclinical models of BRAF V600X melanoma, CRC, NSCLC, and brain metastasis
2024 · Bridget Kreger, Jacob R. Stephenson, et al. · Cancer Research · 1
Design, synthesis and biological evaluation of macrocyclic NTRK heterobifunctional degraders
2026 · Corey Anderson, Jennifer Han-Chun Tsai, et al. · Bioorganic & Medicinal Chemistry Letters
Abstract PR11: Understanding the role of myddosome dynamics in melanoma using live cell imaging
2020 · Bridget Kreger, Adam Hendricks · Cancer Research
Extracellular Vesicles And Their Role In Cancer Progression And Therapy Resistance
2016 · Kreger, Bridget · eCommons (Cornell University)
Abstract LB-025: Survivin is trafficked into cancer cell-derived exosomes via a microtubule-dependent mechanism
2015 · Bridget T. Kreger, Marc Antonyak, et al. · Cancer Research
Works count: 16
Citation count: 1,832
H-index: 9
I10-index: 9
Year
Topic
Type